{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T17:22:55Z","timestamp":1768929775901,"version":"3.49.0"},"reference-count":76,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,2,23]],"date-time":"2014-02-23T00:00:00Z","timestamp":1393113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Digoxin improves exercise tolerance and reduces hospitalizations in patients with systolic heart failure, but its use has declined progressively for the past two decades. The Digitalis Investigation Group trial showed that digoxin reduced hospitalizations but had a neutral effect on total mortality. There was evidence that mortality caused by worsening heart failure was less, but there was also a signal suggesting an increase in other cardiac (presumed arrhythmic) death. Use of digoxin has declined substantially and recent guideline recommendations have significantly de-emphasized the importance of this drug in the management of heart failure. Two developments suggest that re-evaluation of the contemporary role of digoxin in the management of heart failure with reduced ejection fraction is warranted. First, heart failure remains progressive, characterized by chronic debility, exercise intolerance, and frequent and costly hospitalizations, despite evidence-based drug and device therapies that prolong survival. Health economics have made reducing hospitalizations in patients with heart failure a major priority. Second, a strong association has emerged between serum concentration and the safety and efficacy of digoxin, which indicates a change in our approach to dosing this agent is needed. Experimental and clinical results suggest that optimizing therapeutic benefit and avoiding harm means dosing to achieve low serum digoxin concentrations (0.5\u20130.9 ng\/mL). Digoxin is an inexpensive agent and the totality of evidence indicates that it reduces hospitalizations and improves symptoms safely when dosed to achieve low serum concentrations. These findings suggest digoxin should have a more prominent therapeutic role in patients with heart failure and reduced ejection fraction.<\/jats:p>","DOI":"10.1002\/ejhf.64","type":"journal-article","created":{"date-parts":[[2014,2,24]],"date-time":"2014-02-24T12:58:32Z","timestamp":1393246712000},"page":"483-493","source":"Crossref","is-referenced-by-count":27,"title":["A Perspective on Re-Evaluating Digoxin's Role in the Current Management of Patients with Chronic Systolic Heart Failure: Targeting Serum Concentration to Reduce Hospitalization and Improve Safety Profile"],"prefix":"10.1093","volume":"16","author":[{"suffix":"Jr","given":"Kirkwood F.","family":"Adams","sequence":"first","affiliation":[{"name":"Departments of Medicine and Radiology, School of Medicine, Division of Cardiology, University of North Carolina at Chapel Hill , Chapel Hill, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalal K.","family":"Ghali","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Mercer University School of Medicine , Macon, GA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Herbert Patterson","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill Eshelman School of Pharmacy , Chapel Hill, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy Gattis","family":"Stough","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Campbell University College of Pharmacy and Health Sciences , Buies Creek, NC ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Emory University , Atlanta, GA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry L.","family":"Bauman","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy Practice and Medicine, Section of Cardiology, Colleges of Pharmacy and Medicine, University of Illinois at Chicago , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector O.","family":"Ventura","sequence":"additional","affiliation":[{"name":"John Ochsner Heart and Vascular Institute, Ochsner Clinical School, The University of Queensland School of Medicine , New Orleans, LA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Sabbah","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Wayne State University, Henry Ford Health System , Detroit, MI ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John I.","family":"Mackowiak","sequence":"additional","affiliation":[{"name":"Center for Outcomes Research , Nashville, TN ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk J.","family":"van Veldhuisen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Groningen, University Medical Center Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,2,23]]},"reference":[{"key":"2026011921114021000_ejhf64-bib-0001","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0002","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"The CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0003","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0004","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"The SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"The Digitalis Investigation Group","year":"1997","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0006","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cardfail.2006.02.005","article-title":"Digoxin use and digoxin toxicity in the post-DIG trial era","volume":"12","author":"Hussain","year":"2006","journal-title":"J Card Fail"},{"key":"2026011921114021000_ejhf64-bib-0007","first-page":"194","article-title":"Trends in the medical management of patients with heart failure","volume":"5","author":"Joffe","year":"2013","journal-title":"J Clin Med Res"},{"key":"2026011921114021000_ejhf64-bib-0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2004.03.004","article-title":"Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design","volume":"148","author":"Fonarow","year":"2004","journal-title":"Am Heart J"},{"key":"2026011921114021000_ejhf64-bib-0009","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jama.289.7.871","article-title":"Association of serum digoxin concentration and outcomes in patients with heart failure","volume":"289","author":"Rathore","year":"2003","journal-title":"JAMA"},{"key":"2026011921114021000_ejhf64-bib-0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jacc.2005.02.091","article-title":"Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis","volume":"46","author":"Adams","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0011","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","article-title":"Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"2026011921114021000_ejhf64-bib-0012","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.amjcard.2007.02.099","article-title":"Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure","volume":"100","author":"Ahmed","year":"2007","journal-title":"Am J Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0013","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2008.06.068","article-title":"Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial","volume":"103","author":"Ahmed","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0014","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/eurjhf\/hft010","article-title":"Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial","volume":"15","author":"Gheorghiade","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011921114021000_ejhf64-bib-0015","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/eurheartj\/eht120","article-title":"Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial","volume":"34","author":"Gheorghiade","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011921114021000_ejhf64-bib-0016","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/eurheartj\/ehs483","article-title":"Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not?","volume":"34","author":"van Veldhuisen","year":"2013","journal-title":"Eur Heart J"},{"key":"2026011921114021000_ejhf64-bib-0017","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/0735-1097(93)90403-N","article-title":"Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group","volume":"22","author":"Uretsky","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study","volume":"329","author":"Packer","year":"1993","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0019","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/0735-1097(93)90579-P","article-title":"Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)","volume":"22","author":"van Veldhuisen","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0735-1097(98)00302-7","article-title":"Superiority of \u2018triple\u2019 drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective randomized study of ventricular function and efficacy of digoxin. randomized assessment of digoxin and inhibitors of angiotensin-converting enzyme","volume":"32","author":"Young","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0021","doi-asserted-by":"crossref","first-page":"48G","DOI":"10.1016\/0002-9149(92)91254-2","article-title":"Review of randomized trials of digoxin therapy in patients with chronic heart failure","volume":"69","author":"Gheorghiade","year":"1992","journal-title":"Am J Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-8703(97)70100-5","article-title":"Digitalis Investigation Group (DIG) trial: a stimulus for further research","volume":"134","author":"Gheorghiade","year":"1997","journal-title":"Am Heart J"},{"key":"2026011921114021000_ejhf64-bib-0023","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0735-1097(94)00417-O","article-title":"Effect of long-term digoxin therapy on autonomic function in patients with chronic heart failure","volume":"25","author":"Krum","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0024","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/0735-1097(95)00285-3","article-title":"Heart rate variability in patients with mild to moderate heart failure: effects of neurohormonal modulation by digoxin and ibopamine. The Dutch Ibopamine Multicenter Trial (DIMT) Study Group","volume":"26","author":"Brouwer","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0025","doi-asserted-by":"crossref","first-page":"19582","DOI":"10.1074\/jbc.M110.119248","article-title":"Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase","volume":"285","author":"Katz","year":"2010","journal-title":"J Biol Chem"},{"key":"2026011921114021000_ejhf64-bib-0026","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1161\/01.CIR.0000132482.95686.87","article-title":"Digoxin in the management of cardiovascular disorders","volume":"109","author":"Gheorghiade","year":"2004","journal-title":"Circulation"},{"key":"2026011921114021000_ejhf64-bib-0027","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1113\/jphysiol.2006.111252","article-title":"The inotropic effect of cardioactive glycosides in ventricular myocytes requires Na+\u2013Ca2+ exchanger function","volume":"575","author":"Altamirano","year":"2006","journal-title":"J Physiol"},{"key":"2026011921114021000_ejhf64-bib-0028","first-page":"H833","article-title":"Acute resetting of carotid sinus baroreceptors. II. Possible involvement of electrogenic Na+ pump","volume":"247","author":"Heesch","year":"1984","journal-title":"Am J Physiol"},{"key":"2026011921114021000_ejhf64-bib-0029","doi-asserted-by":"crossref","first-page":"H1781","DOI":"10.1152\/ajpheart.00707.2004","article-title":"Digitalis: new actions for an old drug","volume":"289","author":"Wasserstrom","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026011921114021000_ejhf64-bib-0030","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"2026011921114021000_ejhf64-bib-0031","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/eurheartj\/ehs004","article-title":"Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure","volume":"33","author":"Castagno","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011921114021000_ejhf64-bib-0032","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.physiol.70.113006.100455","article-title":"Calcium cycling and signaling in cardiac myocytes","volume":"70","author":"Bers","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"2026011921114021000_ejhf64-bib-0033","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJM199812173392503","article-title":"A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators","volume":"339","author":"Cohn","year":"1998","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0034","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199111213252103","article-title":"Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group","volume":"325","author":"Packer","year":"1991","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0140-6736(90)91517-E","article-title":"Xamoterol in severe heart failure","volume":"336","author":"The Xamoterol in Severe Heart Failure Study Group","year":"1990","journal-title":"Lancet"},{"key":"2026011921114021000_ejhf64-bib-0036","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jacc.2005.03.051","article-title":"In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"46","author":"Abraham","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0037","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0038","first-page":"287","article-title":"Classical concentration\u2013response relationship between serum digoxin level and contractility indices","volume":"27","author":"Buch","year":"1980","journal-title":"Dan Med Bull"},{"key":"2026011921114021000_ejhf64-bib-0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00609753","article-title":"Dose\u2013response relationships and plasma concentrations of digitalis glycosides in man","volume":"13","author":"Belz","year":"1978","journal-title":"Eur J Clin Pharmacol"},{"key":"2026011921114021000_ejhf64-bib-0040","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/0002-9149(75)90828-0","article-title":"Dose\u2013response relation between therapeutic levels of serum digoxin and systolic time intervals","volume":"35","author":"Hoeschen","year":"1975","journal-title":"Am J Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0041","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1161\/01.CIR.50.1.94","article-title":"Effects of maintenance digoxin therapy on systolic time intervals and serum digoxin concentrations","volume":"50","author":"Carliner","year":"1974","journal-title":"Circulation"},{"key":"2026011921114021000_ejhf64-bib-0042","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1161\/01.CIR.92.7.1801","article-title":"Effects of increasing maintenance dose of digoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin-converting enzyme inhibitors","volume":"92","author":"Gheorghiade","year":"1995","journal-title":"Circulation"},{"key":"2026011921114021000_ejhf64-bib-0043","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0735-1097(02)01708-4","article-title":"Clinical benefits of low serum digoxin concentrations in heart failure","volume":"39","author":"Adams","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0044","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa021266","article-title":"Sex-based differences in the effect of digoxin for the treatment of heart failure","volume":"347","author":"Rathore","year":"2002","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0045","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMp020118","article-title":"Digoxin \u2013 new perspective on an old drug","volume":"347","author":"Eichhorn","year":"2002","journal-title":"N Engl J Med"},{"key":"2026011921114021000_ejhf64-bib-0046","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1161\/CIRCHEARTFAILURE.109.859322","article-title":"Digoxin: quo vadis?","volume":"2","author":"Cleland","year":"2009","journal-title":"Circ Heart Fail"},{"key":"2026011921114021000_ejhf64-bib-0047","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijcard.2012.04.074","article-title":"A new indication for digoxin: to enable introduction and dose-escalation of ss-blocker therapy in severe heart failure","volume":"158","author":"Tan","year":"2012","journal-title":"Int J Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0048","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/CIRCOUTCOMES.111.000079","article-title":"Effectiveness and safety of digoxin among contemporary adults with incident systolic heart failure","volume":"6","author":"Freeman","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026011921114021000_ejhf64-bib-0049","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1532-5415.1999.tb01603.x","article-title":"Assessment and control for confounding by indication in observational studies","volume":"47","author":"Psaty","year":"1999","journal-title":"J Am Geriatr Soc"},{"key":"2026011921114021000_ejhf64-bib-0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jclinepi.2004.03.011","article-title":"Methods to assess intended effects of drug treatment in observational studies are reviewed","volume":"57","author":"Klungel","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2026011921114021000_ejhf64-bib-0051","first-page":"51476","article-title":"Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and FY 2012 rates; hospitals' FTE resident caps for graduate medical education payment. Final rules","volume":"76","year":"2011","journal-title":"Fed Regist"},{"key":"2026011921114021000_ejhf64-bib-0052","first-page":"26490","article-title":"Medicare program; hospital inpatient value-based purchasing program. Final rule","volume":"76","year":"2011","journal-title":"Fed Regist"},{"key":"2026011921114021000_ejhf64-bib-0053","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.amjmed.2013.02.001","article-title":"Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure","volume":"126","author":"Bourge","year":"2013","journal-title":"Am J Med"},{"key":"2026011921114021000_ejhf64-bib-0054","first-page":"178","article-title":"Heart failure in the lifetime of Musca Domestica (The Common Housefly)","volume":"1","author":"Konstam","year":"2013","journal-title":"JCHF"},{"key":"2026011921114021000_ejhf64-bib-0055","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA"},{"key":"2026011921114021000_ejhf64-bib-0056","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.cardfail.2012.02.005","article-title":"Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction","volume":"18","author":"Butler","year":"2012","journal-title":"J Card Fail"},{"key":"2026011921114021000_ejhf64-bib-0057","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"2026011921114021000_ejhf64-bib-0058","doi-asserted-by":"crossref","DOI":"10.1093\/eurjhf\/hft095","article-title":"Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document","author":"Zannad","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026011921114021000_ejhf64-bib-0059","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0002-9343(74)90769-4","article-title":"A nomogram for digoxin therapy","volume":"57","author":"Jelliffe","year":"1974","journal-title":"Am J Med"},{"key":"2026011921114021000_ejhf64-bib-0060","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1001\/archinte.166.22.2539","article-title":"A method of determining the dose of digoxin for heart failure in the modern era","volume":"166","author":"Bauman","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026011921114021000_ejhf64-bib-0061","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1046\/j.1365-2710.2002.00418.x","article-title":"Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyperbolic model based on creatinine clearance","volume":"27","author":"Konishi","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"2026011921114021000_ejhf64-bib-0062","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/qjmed\/hcq196","article-title":"Individual dosage of digoxin in patients with heart failure","volume":"104","author":"Muzzarelli","year":"2011","journal-title":"QJM"},{"key":"2026011921114021000_ejhf64-bib-0063","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0002-9149(78)90724-5","article-title":"Correlative studies of serum digitalis levels and the arrhythmias of digitalis intoxication","volume":"41","author":"Shapiro","year":"1978","journal-title":"Am J Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0064","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","article-title":"What is the optimal serum potassium level in cardiovascular patients?","volume":"43","author":"Macdonald","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0065","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.amjcard.2012.02.028","article-title":"Therapeutic ranges of serum digoxin concentrations in patients with heart failure","volume":"109","author":"Goldberger","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0066","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1001\/jamainternmed.2013.7756","article-title":"Reference Laboratory Values for Digoxin Following Publication of Digitalis Investigation Group (DIG) Trial Data","volume":"173","author":"Hauptman","year":"2013","journal-title":"JAMA Intern Med"},{"key":"2026011921114021000_ejhf64-bib-0067","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1161\/hc4901.102568","article-title":"ACC\/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America","volume":"104","author":"Hunt","year":"2001","journal-title":"Circulation"},{"key":"2026011921114021000_ejhf64-bib-0068","first-page":"e154","article-title":"ACC\/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation"},{"key":"2026011921114021000_ejhf64-bib-0069","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2008.11.013","article-title":"2009 Focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"53","author":"Hunt","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0070","article-title":"ACCF\/AHA Guideline for the Management of Heart Failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"2013","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011921114021000_ejhf64-bib-0071","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/eurheartj\/ehi204","article-title":"Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology","volume":"26","author":"Swedberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2026011921114021000_ejhf64-bib-0072","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"2026011921114021000_ejhf64-bib-0073","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2026011921114021000_ejhf64-bib-0074","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1071-9164(99)91340-4","article-title":"Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction \u2013 pharmacological approaches","volume":"5","author":"Adams","year":"1999","journal-title":"J Card Fail"},{"key":"2026011921114021000_ejhf64-bib-0075","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2005.11.005","article-title":"HFSA 2006 Comprehensive Heart Failure Practice Guideline","volume":"12","author":"Adams","year":"2006","journal-title":"J Card Fail"},{"key":"2026011921114021000_ejhf64-bib-0076","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2010.04.004","article-title":"HFSA 2010 comprehensive heart failure practice guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J Card Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.64","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/16\/5\/483\/66434613\/eurjhf_16_5_483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/16\/5\/483\/66434613\/eurjhf_16_5_483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:13:05Z","timestamp":1768875185000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/16\/5\/483\/8427754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,23]]},"references-count":76,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,2,23]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.64","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,5]]},"published":{"date-parts":[[2014,2,23]]}}}